Crystal structure of Saccharomyces cerevisiae 6-phosphogluconate dehydrogenase Gnd1
© He et al; licensee BioMed Central Ltd. 2007
Received: 23 March 2007
Accepted: 14 June 2007
Published: 14 June 2007
As the third enzyme of the pentose phosphate pathway, 6-phosphogluconate dehydrogenase (6PGDH) is the main generator of cellular NADPH. Both thioredoxin reductase and glutathione reductase require NADPH as the electron donor to reduce oxidized thioredoxin or glutathione (GSSG). Since thioredoxin and GSH are important antioxidants, it is not surprising that 6PGDH plays a critical role in protecting cells from oxidative stress. Furthermore the activity of 6PGDH is associated with several human disorders including cancer and Alzheimer's disease. The 3D structural investigation would be very valuable in designing small molecules that target this enzyme for potential therapeutic applications.
The crystal structure of 6-phosphogluconate dehydrogenase (6PGDH/Gnd1) from Saccharomyces cerevisiae has been determined at 2.37 Å resolution by molecular replacement. The overall structure of Gnd1 is a homodimer with three domains for each monomer, a Rossmann fold NADP+ binding domain, an all-α helical domain contributing the majority to hydrophobic interaction between the two subunits and a small C-terminal domain penetrating the other subunit. In addition, two citrate molecules occupied the 6PG binding pocket of each monomer. The intact Gnd1 had a Km of 50 ± 9 μM for 6-phosphogluconate and of 35 ± 6 μM for NADP+ at pH 7.5. But the truncated mutants without the C-terminal 35, 39 or 53 residues of Gnd1 completely lost their 6PGDH activity, despite remaining the homodimer in solution.
The overall tertiary structure of Gnd1 is similar to those of 6PGDH from other species. The substrate and coenzyme binding sites are well conserved, either from the primary sequence alignment, or from the 3D structural superposition. Enzymatic activity assays suggest a sequential mechanism of catalysis, which is in agreement with previous studies. The C-terminal domain of Gnd1 functions as a hook to further tighten the dimer, but it is not necessary for the dimerization. This domain also works as a lid on the substrate binding pocket to control the binding of substrate and the release of product, so it is indispensable for the 6PGDH activity. Moreover, the co-crystallized citrate molecules, which mimic the binding mode of the substrate 6-phosphogluconate, provided us a novel strategy to design the 6PDGH inhibitors.
The 6-phosphogluconate dehydrogenase (6PGDH, EC 126.96.36.199) is the third enzyme of the oxidative branch of the pentose phosphate pathway. This pathway has two major functions: the production of ribulose 5-phosphate which is required for the nucleotide synthesis, and the generation of NADPH which provides the major reducing power essential for protecting the cell against oxidative stress and a variety of reductive biosynthetic reactions, particularly lipid production. Both thioredoxin reductase and glutathione reductase require NADPH as the electron donor to reduce oxidized thioredoxin or glutathione (GSSG). Since thioredoxin and GSH are important antioxidants, it is not surprising that 6PGDH plays a critical role in protecting cells from oxidative stress. Recently there is renewed interest in this pathway since it has been shown to play a central role in tumor proliferation process[3, 4]. The 6PGDH catalyzes the oxidative decarboxylation of 6-phosphogluconate (6PG) to ribulose 5-phosphate (Ru5P) and CO2 with the concomitant reduction of NADP+ to NADPH. This reaction is similar to those catalyzed by isocitrate dehydrogenase (IDH) and malic enzyme because all three yield a ketone, CO2, and NAD(P)H as products. However, unlike the other enzymes, 6PGDH is metal-ion independent.
The enzyme 6PGDH has been reported to be involved in several human diseases, including cancer and Alzheimer's disease(AD), through various studies over the last three decades [9–11]. One of the correlations between 6PGDH and these diseases is oxidative stress. As we all know cancer is a genetic disease. Oxidative stress induces DNA damage including modified base products and strand breaks that may lead to further mutation and chromosomal aberration of cancer. Although it remains an open question as to whether oxidative stress is a causative factor or a consequence of AD, the correlation between oxidative stress and AD is well established. Many evidence suggested that increased oxidative damage is an early event in AD. As a compensatory response to elevated brain oxidative stress, the activities of 6PGDH were increased in AD.
The kinetic mechanism of the enzymes from sheep liver[6, 17–20] and from Candida utilis has been studied in detail. A considerable number of factors are capable of modifying the catalytic activity of 6PGDH. From the sheep liver 6PGDH, the oxidative decarboxylation reaction was reported as asymmetric in terms of ordered product release: carbon dioxide first and NADPH last, while the favored binding order for NADP+ and 6PG is dependent on the buffer system used. In phosphate buffer, it seems that NADP+ binds to the enzyme before 6PG, but in triethanolamine (TEA) buffer at pH 7.0 it seems that an initial complex composed of the enzyme and 6PG is dominant. In either buffer product release is in the same order with carbon dioxide leaving first, followed by Ru5P. Multiple isotope effects have been used to interpret the sequential mechanism. However, a recent investigation under a wider range of conditions suggests an acid-base mechanism[23, 24]. The general base accepts a proton from the 3-hydroxyl group of 6PG concomitant with hydride transfer and then shuttles the proton between itself and the sugar oxygen throughout the reaction, ultimately accepting it as ribulose is formed. The general acid presumably plays a role in only the last of the three steps, namely, the tautomerization of the enediol of ribulose 5-phosphate to the keto product.
Due to the potential importance of 6PGDH in human diseases and medicine (i.e., development of selective inhibitors for therapeutic approaches), it is crucial to better understand its molecular function through the 3D structural studies of this enzyme from multiple species. So far 6PGDH crystal structures have been solved in the three species (sheep[27, 28], T. brucei and L. lactis). Since yeasts are comparatively similar in structure to human cells, both being eukaryotic, in contrast to the bacteria and archaea, we examined the structural and biochemical characteristics of 6PGDH in S. cerevisiae, which is one of the most intensively studied eukaryotic model organisms.
In S. cerevisiae, the open reading frame YHR183W/GND1 encodes the major isoform of the two 6PGDHs, named Gnd1, accounting for approximately 80% of the total 6PGDH activity, whereas Gnd2 encodes the minor isoform. Gnd1 displays very high similarity to Gnd2 (86% identity). In this study we overexpressed, purified and characterized Gnd1 in E. coli. Moreover, we determined the crystal structure of Gnd1 in complex with two citrate molecules by molecular replacement and refined it to 2.37 Å resolution. Based on the comparative structural analyses in combination with the enzymatic kinetics studies, we obtained more insights into the molecular mechanism of this enzyme, especially the structure-based function of the C-terminal domain.
Results and discussion
Data Collection and Refinement Statistics.
Unit-cell parameters (Å)
a = b = 147.26, c = 114.42,α=β = 90°, γ = 120°
Completeness (%), overall/outer shell
Resolution range (Å), overall/outer shell
Rmergea (%) overall/outer shell
Number of atoms
Rms deviation from targetd
Bond lengths (Å)
Bond angles (°)
Average B factors:
Ramachandran plot (%)e
Similar to the 6PGDHs reported in other species, Gnd1 forms dimer. Each subunit has three domains (A, B and C in Figure 2B). Domain A includes a typical dinucleotide binding motif-"Rossmann Fold" (residues 1 to 127) and two additional α/β units (residues 128 to 175) which form the N-terminal α/β "co-enzyme binding" domain. This domain exhibits high similarity to other NADP+ binding domains such as the 3-hydroxyisobutyrate dehydrogenase (HIBADH) from Thermus thermophilus HB8, with a root-mean-square deviation (rmsd) of 2.3 Å. This data substantiates previous phylogenetic evidence that 6PGDH and HIBADH may share a common evolutionary origin and enzymatic mechanism. Domain B consists of residues 176–433 and is almost exclusively helical in structure(αH-αT). Domain C (residues 434 to 476) contains one helix (αU) and one loop (Figure 2B). The two all-α domains contain most of the residues involved in substrate binding and dimerization. The dimer is formed by the C-terminal tail of two subunits threading through each other forming a mobile lid on the substrate binding pocket.
The penetration of the third domain through the other monomer in the biological unit indicates a concerted folding pathway of the monomers during the translational or post-translational process. Although the mean average temperature factor of Gnd1 is as high as 49.1, we still found a difference of temperature factor among the three domains, which are 58.0, 42.5 and 53.5 respectively. This is consistent with previous observations from the structures of 6PGDH from sheep liver and protozoan parasite, which showed the first domain's higher mobility in the absence of dinucleotide co-enzyme[28, 29]. Gnd1 and 6PGDH of sheep liver both have smaller dimer interface of around 5500 Å2 compared to the 6PGDH of T. brucei, which is around 6300 Å2. This is likely due to fewer residues (109 and 115 vs 134 amino acids) involved in the monomer-monomer interactions of the yeast Gnd1 and sheep 6PDGH.
Through the analysis of the surface potential, it is obvious that dimerization is not completely due to the interaction between the C-termini of each monomer. In fact, the interactions between the hydrophobic groups of Domain B of each monomer contribute the majority to the dimerization.
The binding of two citrate molecules
To our surprise, two citrate molecules were bound to the active site of each Gnd1 monomer (Figure 3). In citrate FLC1, Oγ2 replaced the water molecule (HOH528) in the structure of 6PGDH-6PG complex (PDB code: 1PGP), hydrogen bonded to Oξ2 of Glu189 and formed a salt bridge with Nη2 of Arg286. OHβ was located within 4 Å from His452 and Arg446 of Chain B, thus its negative charge is balanced by these two residues. In citrate FLC2, Oα2 interacted electrostatically with His452 in Chain B, while Oα1 did not form any hydrogen bonds, nor salt bridges, with other residues. The role of O3 in 6PG was substituted partly by Oγ1, interacting with Asn102; and partly by Oγ2, interacting with Asn186 and Lys182. Oβ1 and Oβ2 located at the same place of O1α and O1 in 6PG respectively. And the position of O2 in 6PG was replaced by OHβ, interacting with Gly129 and Gly130.
Comparison of residues interacting with two citrate molecules (FLC1 and FLC2) in Gnd1 and Gluconate-6-phosphate (6PG) in sheep liver 6PGDH (PDB code: 1PGP). (Except for Arg446 and His452, all other residues are in chain A.)
Arg446 (chain B)
Arg446 (chain B)
His452 (chain B)
His452 (chain B)
Human African trypanosomiasis (sleeping sickness) has re-emerged as a major health threat in Sub-Saharan Africa which caused by parasitic protozoan Trypanosoma brucei. 6PGDH emerges as a potential drug target in this disease. Previous study has shown that citrate serves as an inhibitor of 6PGDH. Structural studies of 6PGDH will definitely facilitate the development of 6PGDH inhibitors for potential therapeutic use. Our current research provides for the first time the conformation of 6PGDH bound with an inhibitor.
The mutant proteins Gnd1ΔC35, Gnd1ΔC39 and Gnd1ΔC53
The yeast Gnd1 consists of 489 residues, with the residues after Ser434 forming a small C-terminal domain. Sequence comparison of the Gnd1 with the corresponding enzymes derived from sheep, E. coli, L. lactis and T. brucei revealed the substrate-binding residues to be identical in all these species, but the sequences of the C-terminal tail are not well conserved, especially the region of residues 457–489 (Figure 1). From the structure of Gnd1 we found two highly conserved residues, Arg446 and His452, to be vitally important for citrate binding. These two residues were also shown to be critical for 6PG binding from structural studies of sheep liver 6PGDH. The residue Arg446 was reported to play an important role in anchoring substrate while 6PG is oxidatively decarboxylated to ribulose 5-phosphate. In an attempt to understand the potential function of the C-terminal tail on the dimerization and enzymatic activity we generated mutant Gnd1 with C-terminal 35, 39 and 53 amino acids deletions. These proteins, designated Gnd1ΔC35, Gnd1ΔC39 and Gnd1ΔC53, which contain residues 1–454, 1–450 and 1–436, were overexpressed and purified, respectively. Gnd1ΔC35 contains both conserved residues (Arg446 and His452), while Gnd1ΔC39 contains only Arg446, and Gnd1ΔC53 is a complete deletion of the entire C-terminal tail (Figure 3B).
Despite the fact that all of the truncated enzymes were soluble and could be purified by Ni2+ chromatography and gel filtration using a Superdex™ 200 column, none of them had detectable enzymatic activity (data not shown). It suggests that the intact C-terminal tail is vitally important for the enzymatic activity, even the region of residues 454–489 is not conserved among different species, nor directly interacting to the substrate 6PG or its homologs.
In addition, through purification and crystallization we found that Gnd1ΔC53 is less stable than the full length Gnd1, although the mutant proteins still dimerized. Obviously the dimerization was not completely sustained by the C-terminal tail. This is the first data to suggest that the C-terminal tail of 6PGDH is dispensable for dimerization. In fact, the interactions of the hydrophobic groups of the Domain B, which are mostly composed of helices, are the major driving force for the dimer formation. However, the C-terminal tail contributes a part to maintaining the stability of the protein.
Km values for the Gnd1
The 6PGDH is an important enzyme of the pentose phosphate pathway and has been linked to several human diseases. Here we provide the X-ray structure of S. cerevisiae 6PGDH/Gnd1. The tertiary structure of Gnd1 exhibits a high similarity to 6PGDH in other species, as well as conserved substrate and coenzyme binding residues. Kinetic studies suggest a sequential mechanism for Gnd1. However, our structure reveals for the first time the binding mode of two inhibitory citrate molecules in the Gnd1 substrate binding pocket, which provides clues for the development of specific inhibitors against 6PGDH. We further studied the role of the Gnd1 C-terminal tail and found that it is dispensable for dimerization, but crucial for the enzymatic activity.
Cloning, expression and purification
The YHR183W/GND1 gene was amplified by PCR using the genomic DNA of S. cerevisiae strain S288C as the template. An additional sequence coding for a six-histidine tag was introduced at the 5' end of the gene during PCR amplification. The PCR product was then cloned into a pET28a-derived vector between Nde I and Not I restriction sites. Expression was done at 37°C using the transformed E. coli Rossetta (DE3) strain and 2 × YT medium (OXOID LTD.) supplemented with kanamycin at 30 μg/ml and chloramphenicol at 34 μg/ml. When the cell culture reached an OD600nm of 0.6, protein expression was induced with 0.2 mM IPTG (BBI) and the cells were grown for a further 4 hrs. Cells were collected by centrifugation, suspended in 30 ml buffer containing 20 mM Tris-HCl, pH 8.0, 200 mM NaCl, 20 mM β-mercaptoethanol and stored overnight at -20°C. Cells were lysed by three cycles of freezing/thawing and sonication. The His-tagged proteins were purified using a Ni2+ affinity column with standard protocols. Eluted protein was further purified by gel filtration using a Superdex™ 200 column (Amersham Biosciences) equilibrated in 20 mM Tris-HCl, pH 8.0, 200 mM NaCl and 20 mM β-mercaptoethanol. The purity of the pooled fractions was checked by SDS-PAGE and the integrity of the protein samples was confirmed by mass spectrometry.
The DNA sequences of GND1 without the sequence coding for the C-terminal 35, 39 and 53 residues (Gnd1ΔC35, Gnd1ΔC39 and Gnd1ΔC53) were amplified, respectively. PCR products were purified using the DNA gel extraction kit (V-gene, China) and inserted into pET28a-derived vector. The mutant proteins (Gnd1ΔC35, Gnd1ΔC39 and Gnd1ΔC53) were overexpressed and purified respectively as described above.
Crystallization of Gnd1
Crystals of Gnd1 were obtained at 15°C by the hanging-drop vapour diffusion method. For crystallization, the protein concentration was 17.3 mg/ml, in a buffer containing 20 mM Tris-HCl, pH 8.0, 50 mM NaCl and 20 mM β-mercaptoethanol. In each drop, 1μl of the protein solution was mixed with 1μl of the reservoir solution and the mixture was equilibrated against 0.5 ml of the reservoir solution (1.28 M tri-Sodium Citrate at pH 6.5). Crystals with a maximal size of 100–200 μm appeared within 3 days. For data collection, the crystals were frozen in liquid nitrogen after soaking in cryoprotectant buffer containing 30% glycerol and 1.28 M tri-Sodium Citrate at pH 6.5.
Data collection and structure determination
The crystal was flash frozen in a stream of nitrogen gas to 110 K. In total 102 images of diffraction data were collected using MAR345dtb detector (MarResearch, Germany), with wavelength of 1.5418 Å and oscillation of 1 degree. X-ray crystallographic data were processed using AUTOMAR. The structure was determined by molecular replacement with the program MOLREP using the structure of 6-PGDH (PDB code: 1PGP) as the initial model. Crystallographic refinement was performed using programs O and CNS. The final model consists of residues 1–476 for one monomer that are visible within the electron density and 212 water molecules. Structure factors and the coordinates have been deposited in the PDB (code: 2P4Q). The final statistics and refinement parameters are listed in Table 1.
Enzymatic activity assays
The assays were performed at 28°C by measuring the initial rate in the direction of oxidative decarboxylation of 6PG. To calculate the specific activity, NADPH production was measured at 340 nm in a MODEL U-2800 UV-VIS spectrophotometer (HITACHI). The enzymes containing 30% glycerol were conserved at -80°C. The standard enzyme assay solution of 200 μl contained (final concentrations): Gly-Gly buffer (50 mM, final pH7.5); MgCl2 (10 mM); NADP+ (0.6 mM); 6PG (2 mM) and enzyme (4.8 nM). All buffers used were prepared with deionized and distilled water. All assays were performed at least in duplicate; means of replicates were used as single points in subsequent statistical analyses. The enzymatic activity of Gnd1, Gnd1ΔC35, Gnd1ΔC39 and Gnd1ΔC53 was measured respectively, as described above.
Determination of kinetic parameters
We would like to thank Mr. Jiang Yu at USTC for assistance for multiple-alignment. We thank Dr. Isaac Mehl at UCSD for critical reading of the paper. We are grateful to Dr. L. D. Warren for providing PyMOL. This work was funded by the projects 2006CB910202 and 2006CB806501 from the Ministry of Science and Technology of China, the grants 30470366 and 30121001 from Chinese National Natural Science Foundation, the 100-Talent Project from Chinese Academy of Science and the start-up fund from USTC.
- Jamieson DJ: Oxidative stress responses of the yeast Saccharomyces cerevisiae. Yeast 1998, 14(16):1511–1527. 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.0.CO;2-SView ArticlePubMedGoogle Scholar
- Carmel-Harel O, Storz G: Roles of the glutathione- and thioredoxin-dependent reduction systems in the Escherichia coli and saccharomyces cerevisiae responses to oxidative stress. Annu Rev Microbiol 2000, 54: 439–461. 10.1146/annurev.micro.54.1.439View ArticlePubMedGoogle Scholar
- Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS, Schirmer WJ: Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 1997, 57(19):4242–4248.PubMedGoogle Scholar
- Nerurkar VR, Ishwad CS, Seshadri R, Naik SN, Lalitha VS: Glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase activities in normal canine mammary gland and in mammary tumours and their correlation with oestrogen receptors. J Comp Pathol 1990, 102(2):191–195.View ArticlePubMedGoogle Scholar
- Pontremoli S, De Flora A, Grazi E, Mangiarottig, Bonsignore A, Horecker BL: Crystalline D-gluconate 6-phosphate dehydrogenase. J Biol Chem 1961, 236: 2975–2980.PubMedGoogle Scholar
- Villet RH, Dalziel K: Studies of 6-phosphogluconate dehydrogenase from sheep liver. 2. Kinetics of the oxidative-decarboxylation reaction, coenzyme binding and analyses for metals. Eur J Biochem 1972, 27(2):251–258. 10.1111/j.1432-1033.1972.tb01834.xView ArticlePubMedGoogle Scholar
- Toyokuni S, Okamoto K, Yodoi J, Hiai H: Persistent oxidative stress in cancer. FEBS Lett 1995, 358(1):1–3. 10.1016/0014-5793(94)01368-BView ArticlePubMedGoogle Scholar
- Palmer AM: The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease. J Neural Transm 1999, 106(3–4):317–328. 10.1007/s007020050161View ArticlePubMedGoogle Scholar
- Caprari P, Caforio MP, Cianciulli P, Maffi D, Pasquino MT, Tarzia A, Amadori S, Salvati AM: 6-Phosphogluconate dehydrogenase deficiency in an Italian family. Ann Hematol 2001, 80(1):41–44. 10.1007/s002770000233View ArticlePubMedGoogle Scholar
- Martins RN, Harper CG, Stokes GB, Masters CL: Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 1986, 46(4):1042–1045. 10.1111/j.1471-4159.1986.tb00615.xView ArticlePubMedGoogle Scholar
- Barretto OC, Nonoyama K, Colletto GM: Acquired erythroenzymopathy in a monozygotic twin with acute myeloid leukemia. Braz J Med Biol Res 1986, 19(1):63–67.PubMedGoogle Scholar
- Moreira PI, Zhu X, Liu Q, Honda K, Siedlak SL, Harris PL, Smith MA, Perry G: Compensatory responses induced by oxidative stress in Alzheimer disease. Biol Res 2006, 39(1):7–13.View ArticlePubMedGoogle Scholar
- Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA: Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001, 60(8):759–767.PubMedGoogle Scholar
- Rosemeyer MA: The biochemistry of glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and glutathione reductase. Cell Biochem Funct 1987, 5(2):79–95. 10.1002/cbf.290050202View ArticlePubMedGoogle Scholar
- Corpet F: Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 1988, 16(22):10881–10890. 10.1093/nar/16.22.10881PubMed CentralView ArticlePubMedGoogle Scholar
- Gouet P, Robert X, Courcelle E: ESPript/ENDscript: Extracting and rendering sequence and 3D information from atomic structures of proteins. Nucleic Acids Res 2003, 31(13):3320–3323. 10.1093/nar/gkg556PubMed CentralView ArticlePubMedGoogle Scholar
- Villet RH, Dalziel K: Studies of 6-phosphogluconate dehydrogenase from sheep liver. 1. Kinetics of the reductive carboxylation reaction. Eur J Biochem 1972, 27(2):244–250. 10.1111/j.1432-1033.1972.tb01833.xView ArticlePubMedGoogle Scholar
- Dyson JE, D'Orazio RE, Hanson WH: Sheep liver 6-phosphogluconate dehydrogenase: isolation procedure and effect of pH, ionic strength, and metal ions on the kinetic parameters. Arch Biochem Biophys 1973, 154(2):623–635. 10.1016/0003-9861(73)90017-9View ArticlePubMedGoogle Scholar
- Li L, Cook PF: The 2'-phosphate of NADP is responsible for proper orientation of the nicotinamide ring in the oxidative decarboxylation reaction catalyzed by sheep liver 6-phosphogluconate dehydrogenase. J Biol Chem 2006, 281(48):36803–36810. 10.1074/jbc.M604609200View ArticlePubMedGoogle Scholar
- Li L, Zhang L, Cook PF: Role of the S128, H186, and N187 triad in substrate binding and decarboxylation in the sheep liver 6-phosphogluconate dehydrogenase reaction. Biochemistry 2006, 45(42):12680–12686. 10.1021/bi0613675View ArticlePubMedGoogle Scholar
- Berdis AJ, Cook PF: Overall kinetic mechanism of 6-phosphogluconate dehydrogenase from Candida utilis . Biochemistry 1993, 32(8):2036–2040. 10.1021/bi00059a021View ArticlePubMedGoogle Scholar
- Rendina AR, Hermes JD, Cleland WW: Use of multiple isotope effects to study the mechanism of 6-phosphogluconate dehydrogenase. Biochemistry 1984, 23(25):6257–6262. 10.1021/bi00320a056View ArticlePubMedGoogle Scholar
- Price NE, Cook PF: Kinetic and chemical mechanisms of the sheep liver 6-phosphogluconate dehydrogenase. Arch Biochem Biophys 1996, 336(2):215–223. 10.1006/abbi.1996.0551View ArticlePubMedGoogle Scholar
- Berdis AJ, Cook PF: Chemical mechanism of 6-phosphogluconate dehydrogenase from Candida utilis from pH studies. Biochemistry 1993, 32(8):2041–2046. 10.1021/bi00059a022View ArticlePubMedGoogle Scholar
- Karsten WE, Chooback L, Cook PF: Glutamate 190 is a general acid catalyst in the 6-phosphogluconate-dehydrogenase-catalyzed reaction. Biochemistry 1998, 37(45):15691–15697. 10.1021/bi9812827View ArticlePubMedGoogle Scholar
- Goulielmos GN, Cosmidis N, Eliopoulos E, Loukas M, Zouros E: Cloning and structural characterization of the 6-phosphogluconate dehydrogenase locus of the medfly Ceratitis capitata and the olive fruit fly Bactrocera oleae. Biochem Biophys Res Commun 2006, 341(3):721–727. 10.1016/j.bbrc.2005.12.222View ArticlePubMedGoogle Scholar
- Adams MJ, Gover S, Leaback R, Phillips C, Somers DO: The structure of 6-phosphogluconate dehydrogenase refined at 2.5 A resolution. Acta Crystallogr B 1991, 47 ( Pt 5): 817–820. 10.1107/S0108768191010315View ArticleGoogle Scholar
- Adams MJ, Ellis GH, Gover S, Naylor CE, Phillips C: Crystallographic study of coenzyme, coenzyme analogue and substrate binding in 6-phosphogluconate dehydrogenase: implications for NADP specificity and the enzyme mechanism. Structure 1994, 2(7):651–668. 10.1016/S0969-2126(00)00066-6View ArticlePubMedGoogle Scholar
- Phillips C, Dohnalek J, Gover S, Barrett MP, Adams MJ: A 2.8 A resolution structure of 6-phosphogluconate dehydrogenase from the protozoan parasite Trypanosoma brucei : comparison with the sheep enzyme accounts for differences in activity with coenzyme and substrate analogues. J Mol Biol 1998, 282(3):667–681. 10.1006/jmbi.1998.2059View ArticlePubMedGoogle Scholar
- Sundaramoorthy R, Iulek J, Barrett MP, Bidet O, Ruda GF, Gilbert IH, Hunter WN: Crystal structures of a bacterial 6-phosphogluconate dehydrogenase reveal aspects of specificity, mechanism and mode of inhibition by analogues of high-energy reaction intermediates. FEBS J 2007, 274(1):275–286. 10.1111/j.1742-4658.2006.05585.xView ArticlePubMedGoogle Scholar
- Sinha A, Maitra PK: Induction of specific enzymes of the oxidative pentose phosphate pathway by glucono-delta-lactone in Saccharomyces cerevisiae. J Gen Microbiol 1992, 138(9):1865–1873.View ArticlePubMedGoogle Scholar
- Vagin A, Teplyakov A: MOLREP: an Automated Program for Molecular Replacement. Acta Crystallogr D Biol Crystallogr 1997, 30(Pt 6):1022–1025.Google Scholar
- Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL: Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998, 54(Pt 5):905–921. 10.1107/S0907444998003254View ArticlePubMedGoogle Scholar
- DeLano WL: The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA, USA 2002. [http://pymol.sourceforge.net/]Google Scholar
- Lokanath NK, Ohshima N, Takio K, Shiromizu I, Kuroishi C, Okazaki N, Kuramitsu S, Yokoyama S, Miyano M, Kunishima N: Crystal structure of novel NADP-dependent 3-hydroxyisobutyrate dehydrogenase from Thermus thermophilus HB8. J Mol Biol 2005, 352(4):905–917. 10.1016/j.jmb.2005.07.068View ArticlePubMedGoogle Scholar
- Hawes JW, Harper ET, Crabb DW, Harris RA: Structural and mechanistic similarities of 6-phosphogluconate and 3-hydroxyisobutyrate dehydrogenases reveal a new enzyme family, the 3-hydroxyacid dehydrogenases. FEBS Lett 1996, 389(3):263–267. 10.1016/0014-5793(96)00597-2View ArticlePubMedGoogle Scholar
- Li L, Dworkowski FS, Cook PF: Importance in catalysis of the 6-phosphate-binding site of 6-phosphogluconate in sheep liver 6-phosphogluconate dehydrogenase. J Biol Chem 2006, 281(35):25568–25576. 10.1074/jbc.M601154200View ArticlePubMedGoogle Scholar
- Bertelli M, El-Bastawissy E, Knaggs MH, Barrett MP, Hanau S, Gilbert IH: Selective inhibition of 6-phosphogluconate dehydrogenase from Trypanosoma brucei . J Comput Aided Mol Des 2001, 15(5):465–475. 10.1023/A:1011196508214View ArticlePubMedGoogle Scholar
- Hanau S, Rinaldi E, Dallocchio F, Gilbert IH, Dardonville C, Adams MJ, Gover S, Barrett MP: 6-phosphogluconate dehydrogenase: a target for drugs in African trypanosomes. Curr Med Chem 2004, 11(19):2639–2650.View ArticlePubMedGoogle Scholar
- Dyson JE, D'Orazio RE: Sheep liver 6-phosphogluconate dehydrogenase. Inhibition by nucleoside phosphates and by other metabolic intermediates. J Biol Chem 1973, 248(15):5428–5435.PubMedGoogle Scholar
- Tetaud E, Hanau S, Wells JM, Le Page RW, Adams MJ, Arkison S, Barrett MP: 6-Phosphogluconate dehydrogenase from Lactococcus lactis : a role for arginine residues in binding substrate and coenzyme. Biochem J 1999, 338 ( Pt 1): 55–60. 10.1042/0264-6021:3380055View ArticleGoogle Scholar
- Hanau S, Rippa M, Bertelli M, Dallocchio F, Barrett MP: 6-Phosphogluconate dehydrogenase from Trypanosoma brucei . Kinetic analysis and inhibition by trypanocidal drugs. Eur J Biochem 1996, 240(3):592–599. 10.1111/j.1432-1033.1996.0592h.xView ArticlePubMedGoogle Scholar
- Rippa M, Giovannini PP, Barrett MP, Dallocchio F, Hanau S: 6-Phosphogluconate dehydrogenase: the mechanism of action investigated by a comparison of the enzyme from different species. Biochim Biophys Acta 1998, 1429(1):83–92.View ArticlePubMedGoogle Scholar